Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 18:13:433-438.
doi: 10.2147/DMSO.S193693. eCollection 2020.

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data

Richard A Chudleigh  1 , Julia Platts  2 , Stephen C Bain  1   3
Affiliations
Review

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data

Richard A Chudleigh et al. Diabetes Metab Syndr Obes. .

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists have been available as glucose-lowering therapies for people with type 2 diabetes since 2006, when twice-daily exenatide was licenced. Since then, advances in peptide chemistry and delivery have allowed for once-daily and more recently once-weekly (QW) delivery of peptides in this class and there are currently three QW "long-acting" GLP-1 receptor agonists available in clinical practice. This short review describes the therapeutic landscape that is occupied by the modern type 2 diabetes glucose-lowering therapies with a particular focus on long-acting GLP-1 receptor agonists. The efficacy and side-effect profiles of the available QW GLP-1 receptor agonists are discussed, focusing on head-to-head clinical trial comparisons. There is also an appraisal of the cardiovascular outcome trials, for which there has been an assessment of each of the QW GLP-1 receptor agonists, leading to clinical conclusions regarding their comparative effectiveness.

Keywords: GLP-1; cardiovascular trial; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Dr Richard A Chudleigh reports personal fees from Novo Nordisk, Eli Lilly, Merck Sharpe & Dohme, Boehringer Ingelheim, Astra Zeneca, Takeda, Napp., outside the submitted work. Professor Stephen Bain reports grants, personal fees, travel support to and registration at medical meetings from Novo Nordisk, Eli Lilly, Sanofi, and Astra Zeneca, outside the submitted work; and Professor Bain has given expert advice on this class of glucose-lowering agents to the National Institute for Health and Care Excellence (NICE) and the All-Wales Medicines Strategy Group. The authors report no other conflicts of interest in this work.

References

    1. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/byetta. Accessed February3, 2020.
    1. Available from: https://www.medicines.org.uk/emc/product/6585/smpc. Accessed February3, 2020.
    1. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/lyxumia. Accessed February3, 2020.
    1. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon. Accessed February3, 2020.
    1. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/eperzan. Accessed February3, 2020.